1-3 of 3
John Sabo
Close
Sort by
Journal Articles

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Ehab L. Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul B. Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan GU, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6389.
https://doi.org/10.1182/blood-2023-186974
Published: 2023
Journal Articles

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Amer M. Zeidan, Amy E. DeZern, Uma Borate, Krissy Kobata, Susan E. Ide, John Sabo, Pedro Marques Ramos, Haiying Sun, Roger M. Lyons, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 4069–4070.
https://doi.org/10.1182/blood-2022-167259
Published: 2022
Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Amer M. Zeidan, Aref Al-Kali, Uma Borate, Thomas Cluzeau, Amy E. DeZern, Jordi Esteve, Aristoteles Giagounidis, Krissy Kobata, Roger Lyons, Uwe Platzbecker, David A. Sallman, Valeria Santini, Guillermo Sanz, Mikkael A. Sekeres, Andrew H. Wei, Zhijian Xiao, Marlies Van Hoef, Claire Nourry-Boulot, Islam Sadek, Bourras-Rezki Bengoudifa, Carolin Sachs, John Sabo, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 4669.
https://doi.org/10.1182/blood-2021-145626
Published: 2021